Prostate Cancer Screening in Singapore

Prostate cancer is the most commonly diagnosed cancer among men, particularly with increasing age. While many prostate cancers grow slowly and may not cause symptoms for years, others can be more aggressive and benefit from early identification and timely medical assessment. Prostate cancer screening in Singapore plays an important role in detecting potential signs of disease at an early stage, supporting informed decision-making and appropriate follow-up.

At the National Cancer Centre Singapore (NCCS), prostate cancer screening is delivered within a structured clinical framework that emphasises early detection, careful risk assessment and coordinated specialist care. Screening services are supported by experienced clinicians, advanced diagnostic capabilities and multidisciplinary expertise, allowing men to receive clear guidance on whether further evaluation or monitoring is needed.

This page explains what prostate cancer screening involves, who may benefit, the screening tests used, and how NCCS supports men through early detection and assessment.

Understanding Prostate Cancer Screening

Prostate cancer screening refers to tests used to assess the risk of prostate cancer in men who do not have symptoms. The aim is not to diagnose cancer immediately, but to identify early changes that may warrant closer monitoring or further investigation.

Screening differs from diagnostic testing, which is performed when symptoms such as urinary difficulties or bone pain are already present. Instead, screening focuses on men who feel well but may be at increased risk due to age, family history or other factors.

Early detection through screening allows doctors and patients to consider a wider range of management options, including active surveillance for low-risk disease or timely treatment for cancers that show signs of progression.

Why Early Detection and Assessment Matter

Prostate cancer often develops gradually and may not cause noticeable symptoms in its early stages. When symptoms do appear, the disease may already be more advanced. Prostate cancer screening supports: 

• Identification of prostate cancer at an earlier stage 
• Better understanding of individual risk 
• Informed decisions about monitoring or treatment 
• Early referral for specialist assessment when required

It is important to note that early detection does not always mean immediate treatment. For many men, screening provides reassurance or supports careful monitoring rather than intervention.

Who Should Consider Prostate Cancer Screening in Singapore

There is no single screening recommendation that applies to all men. Decisions about prostate cancer screening should be individualised, taking into account personal risk factors and preferences.

Men Who May Benefit From Screening

Prostate cancer screening may be appropriate for men who:

• Are aged 50 years and above 
• Have a family history of prostate cancer, particularly in first-degree relatives 
• Carry certain inherited genetic mutations associated with higher risk 
• Are concerned about prostate health and wish to understand their risk

Men with higher-risk profiles may be advised to begin screening earlier, often from their mid-40s, following discussion with a healthcare professional.

Prostate-Specific Antigen (PSA) Testing

PSA testing is a key component of prostate cancer screening. PSA is a protein produced by the prostate gland, and elevated levels may be associated with prostate cancer.

However, PSA levels can also be influenced by non-cancerous conditions such as prostate enlargement or inflammation. For this reason, PSA testing is not used in isolation, but interpreted alongside clinical findings and individual risk factors.

At NCCS, PSA results are reviewed carefully to determine whether further assessment is needed, rather than relying on a single threshold value.

Clinical Assessment and Physical Examination

In some cases, screening may also include a digital rectal examination (DRE). This allows clinicians to assess the size, shape and texture of the prostate and identify abnormalities that may not be reflected in PSA levels.

Clinical assessment helps provide a more complete picture of prostate health and supports informed decision-making about next steps.

Advanced Imaging and Further Assessment

If screening results suggest an increased risk of prostate cancer, further evaluation may be recommended. This can include:

• MRI of the prostate, which provides detailed imaging of prostate tissue
• Targeted assessment to identify areas that may require closer monitoring 
• Consideration of prostate biopsy in selected cases

These investigations are not part of routine screening but are used when screening results indicate the need for further clarification.

Understanding Screening Results

Screening results can generally be grouped into three broad categories:

Normal Results

Normal screening results indicate no concerning findings at the time of assessment. Men are typically advised on appropriate follow-up intervals based on age and risk profile.

Borderline or Mildly Elevated Results

Some men may have PSA levels that are slightly elevated or show gradual changes over time. In such cases, repeat testing or closer monitoring may be recommended rather than immediate further investigation.

Abnormal Results

Abnormal screening results may prompt additional imaging or specialist assessment. Importantly, abnormal results do not automatically mean cancer is present, but they do require careful evaluation.

Active Surveillance and Early-Stage Prostate Cancer

One of the key benefits of early detection through screening is the option of active surveillance for men with low-risk prostate cancer.

Active surveillance involves:

• Regular PSA testing 
• Periodic imaging 
• Repeat assessment when indicated

This approach allows treatment to be delayed or avoided unless there is evidence of disease progression, helping preserve quality of life while maintaining close medical oversight.

Benefits and Limitations of Prostate Cancer Screening

Benefits

• Early identification of prostate cancer 
• Better understanding of personal risk 
• More management options, including surveillance 
• Reassurance for men with normal results

Limitations

• Screening does not detect all prostate cancers 
• PSA testing may produce false-positive results
• Some detected cancers may never cause harm 
• Additional tests may be required to clarify findings

At NCCS, these benefits and limitations are discussed openly to support informed decision-making.

Prostate Cancer Screening as Part of Men’s Health

Prostate cancer screening is often part of a broader discussion about men’s health. Screening consultations may also address:

• Urinary symptoms 
• Sexual health concerns 
• Family history of cancer 
• Lifestyle factors that influence long-term health

This holistic approach supports better overall health outcomes and encourages proactive health management.

When Prostate Cancer Screening May Not Be Suitable

Screening may not be appropriate for all men, particularly those with significant medical conditions or limited life expectancy. In such cases, the potential benefits of screening may be outweighed by the risks of further testing.

Individual circumstances and preferences are always considered when discussing screening options.

Commonly Asked Questions

Does prostate cancer screening prevent cancer?

Screening does not prevent cancer, but it may help detect prostate cancer at an earlier stage.

Is PSA testing painful?

No. PSA testing involves a simple blood test.

How often should screening be done?

Screening intervals vary depending on age, PSA levels and individual risk factors.

Will I need treatment if cancer is detected?

Not always. Some prostate cancers are managed with active surveillance rather than immediate treatment.

How long does it take to receive prostate cancer screening results?

PSA blood test results are usually available within a few working days. If further tests are needed, results may take longer and will be discussed during follow-up at the National Cancer Centre Singapore (NCCS).